
r_{s}

pvalue


Pantomics TMA

0.49

< 0.001*

All samples (n = 59)
  
Histological grade
  
I (n = 2)

N/D

N/D

II (n = 22)

0.61

0.002*

III (n = 35)

0.55

0.001*

Stage
  
Early n = 47

0.56

< 0.001*

Advanced n = 12

0.72

0.008*

HER2
  
Negative n = 21

0.82

< 0.001*

Positive n = 38

0.47

0.003*

ER
  
Negative n = 33

0.6

< 0.001*

Positive n = 26

0.57

0.003*

PR
  
Negative n = 29

0.67

< 0.001*

Positive n = 30

0.49

0.006*

AMC samples
  
All samples (n = 68)

0.59

< 0.0001*

Histological grade
  
I (n = 10)

0.69

0.039*

II (n = 35)

0.53

0.001*

III (n = 23)

0.27

0.22

Stage
  
Early n = 44

0.54

< 0.001*

Advanced n = 24

0.49

0.05

HER2
  
Negative n = 50

0.54

< 0.001*

Positive n = 18

0.4

0.1862

ER
  
Negative n = 23

0.63

0.001*

Positive n = 45

0.34

0.02*

PR
  
Negative n = 32

0.53

0.002*

Positive n = 36

0.42

0.01*

Metastasis
  
No (n = 64)

0.49

< 0.001*

Distant (n = 4)

0.63

N/D

Nodal status
  
0 (n = 32)

0.49

0.005*

1 (n = 36)

0.51

0.002*

Tumor recurrence
  
No (n = 49)

0.49

< 0.001*

Yes (n = 19)

0.3

0.21

 Spearman’s rank correlation coefficient (r_{s}) tests were performed on the Pantomics TMA to test for correlation between α3 and COX2 expression within all samples (n = 59), or within subgroups of various clinicopathologic features including tumor grade, disease stage, or hormone receptor status. AMC samples (n = 68) were also assessed together, or within the same subgroups, as well as with regard to metastasis, lymph node status, and tumor recurrence. N/D, no data. *p < 0.05 is considered statistically significant; all significant values are shown in bold.